Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Moderna and the US Biomedical Advanced Research and Development Authority (BARDA) have updated their contract for an additional funding commitment of up to $472m.
The funding will support the late-stage clinical development of the company’s Covid-19 vaccine candidate, mRNA-1273, including the expanded Phase III clinical trial.
Previously, BARDA agreed to provide up to $483m for the scale-up of the vaccine and clinical development, which was supposed to involve a smaller number of participants in the Phase III study.